Bio-Rad Laboratories Inc (BIO) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics.
Total Assets Chart for Bio-Rad Laboratories Inc
Bio-Rad Laboratories Inc (BIO) total assets for FY2025 were USD 10.6B, a 12.9% change from FY2024. Bio-Rad Laboratories Inc's total assets grew from USD 71.5M in 1985 to USD 10.6B in 2025 (14692.3% over 40 years). Total assets compound annual growth rate: 5-year CAGR of -4.0%, 10-year CAGR of 11.0%, 20-year CAGR of 10.5%.
Total Assets (US Dollars)
R&D as % of Revenue
Key Stats
- Market Cap
- $9.87B
- Implied Share Price
- $454.85
- Enterprise Value
- $9.81B
- Revenue (TTM)
- $2.59B
- EBITDA
- $441.00M
- Profit Margin
- 8.59%
- Trailing P/E
- 48.15
- Forward P/E
- 41.32
- Price/Book (MRQ)
- 1.41
- Price/Sales (TTM)
- 3.81
- EV/EBITDA
- 17.28
- EV/Revenue
- 3.79
- Dividend Yield
- —
- Book Value
- $268.30
- Free Cash Flow (FY2025)
- $374.60M
- Free Cash Flow Yield
- 3.80%
Snapshot as of 6th October 2026 — not point-in-time controlled, may lag the live market by a few days.